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1. Introduction 
Sjogren's syndrome (SS) is a systemic autoimmune disease characterised by 
dysfunctions of the lachrymal, salivary and occasionally other exocrine glands, leading to 
mucosal dryness, and by a variety of extraglandular organ manifestations [1,2]. The 
diagnostic hallmarks of the disease are the subjective and objective signs of ocular and oral 
dryness termed keratoconjunctivitis sicca and xerostomia. The disease is associated with a 
chronic inflammatory cell infiltration of the involved organs, the predominant cell type in the 
infiltration being CD4-positive T-lymphocytes [3]. A B-lymphocyte hyperactivity is featured 
by hypergammaglobulinaemia, the presence of autoantibodies and, as an ultimate stage in a 
minority of the cases, the development of malignant B-cell lymphoma [4]. The syndrome can 
present in association with other systemic autoimmune diseases (i.e. systemic lupus 
erythematosus, rheumatoid arthritis [RA], systemic sclerosis, etc.), in which case it is termed 
secondary SS, or it can manifest as a separate entity, designated primary SS (pSS). 
pSS is one of the most common systemic autoimmune diseases; its prevalence among 
adult females is estimated to be around 0.6% [5]. However, rather different prevalence 
figures have also been published, ranging from 2.7% in an elderly population [6] to 0.4% in a 
study focusing on autoantibody determinations [7]. This wide variety certainly reflects 
differences in the diagnostic criteria applied (5,7). It is about 20 times more frequent among 
females than among males [8]. In addition to the lachrymal and the salivary glands, 
dysfunctions can also occur in the exocrine glands of the upper airways, the gastrointestinal 
tract, the vagina and the skin, leading to bronchitis sicca, atrophic gastritis, vaginitis sicca and 
skin dryness, respectively. The most common extraglandular manifestation in pSS is a non-
erosive polyarthritis occurring in as many as 90% of the patients [9]. Further organ 
involvements, such as Raynaud's phenomenon, renal tubular acidosis occurring alone or 
together with other signs of a chronic tubulointerstitial nephritis, small vessel vasculitis and 
pulmonary fibrosis are encountered in 10-30% of the patients [2,9,10]. Although the overall 
mortality does not seem to be higher in pSS than in the general population [11], malignant 
lymphoma or certain other manifestations can lead to a life-endangering state, and the 
morbidity due to the various clinical symptoms is almost always high [4]. 
5 
The diagnosis of pSS requires the fulfilment of various diagnostic criteria. The first 
classification system was the Copenhagen criteria [12], while later independent groups 
established further systems: the San Diego [13], the Japanese [14], the Scandinavian [15] and 
the Greek [16] criteria. Subsequently, the European Community criteria were introduced [17] 
and gained wide acceptance. These criteria differed from each other in certain important 
points, and therefore they identified rather different patient populations which greatly 
hampered the evaluation of various studies of pSS patients [18]. Although the two most 
widely used criterion systems were recently unified as the American-European classification 
criteria [19], all of these diagnostic approaches require various invasive investigations (labial 
biopsy and sialography). The search for simple, non-invasive diagnostic methods therefore 
remains an important issue. Our group has made considerable efforts to assess the value of 
parotid gland ultrasonography and magnetic resonance imaging (MRI) in the diagnosis and 
follow-up of pSS patients [20,21]. 
With the involvement of 62 pSS patients and 63 controls, we demonstrated that the 
sonographic results (in particular the presence or absence of a parotid gland inhomogeneity) 
were in very good accordance with the parotid sialographs and scintigraphic findings and the 
histologic results on the minor salivary glands. The MRI studies led to similar conclusions. 
There was good agreement between the MRI and the ultrasonographic findings both in the 
pSS cases (93.2%) and in the controls (86.5%). In one pSS patient who developed parotid 
lymphoma, ultrasonography revealed a hypoechoic "cobblestone'Mike inhomogeneous 
internal pattern which was coupled with an almost homogeneous MRI pattern. As similar 
results were later observed in further pSS patients with lymphoma, we proposed that this 
combination of echographic and MRI patterns may be characteristic of a lymphoma. In view 
of the high specificity and sensitivity of the ultrasonographic examination, and also its 
favourable cost, relative simplicity and wide availability, we suggested that this examination 
should be incorporated in the diagnostic criteria of pSS. As the MRI examination did not 
prove to be superior in diagnostic value to ultrasonography, we concluded that this imaging 
technique should be reserved for special cases. 
While the classical glandular signs and symptoms of SS have been clarified more than 
70 years ago [22], our knowledge of the clinical spectrum of the disease has continuously 
grown during the past few decades. Systematic examination of certain organs, i.e. the stomach 
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[23], the kidney [24,25], the peripheral nervous system [26,27] and the lung [28], has 
significantly widened our perspectives concerning pSS, as these investigations have revealed 
abnormalities in great proportions of the examined patients. Nevertheless, data on the 
involvement of another organ system of vital importance, the cardiovascular system, were 
somewhat scarce and inconclusive [29,30]). Despite the severe oral symptoms and 
pathological findings, little was earlier known about the oesophageal motor function either 
[31,32]. Accordingly, one of my activities involved participation in clinical studies of the 
cardiac and oesophageal functions in pSS patients. 
The classical concept of the origin of the sicca symptoms in pSS was that a 
progressive loss of functioning glandular tissue caused by a chronic inflammation leads to 
irreversible end-organ damage and a consecutive cessation of secretion. However, this 
concept is now undergoing profound modification [18,33-35]. The symptoms of dryness and 
the quantitatively determined saliva and tear production may vary greatly during the course of 
the disease, even without treatment, and their spontaneous improvement is often observed for 
varying periods [36]. A marked discrepancy has been reported between the degree of exocrine 
insufficiency and the histologically verified intensity of the inflammatory infiltration in the 
salivary glands [37]. These data suggest that the sicca symptoms may partly be consequences 
of certain potentially reversible factors distinct from irreversible organ destruction. Oral 
dryness is a common side-effect of drugs with anticholinergic action. An autonomic 
neuropathy has been implicated in the elicitation of oral and ocular dryness in patients with 
diabetes mellitus [38-39]. Occasional case reports [40-43] and clinical trials involving small 
series of patients [44-50] have been published concerning an autonomic neuropathy in pSS. 
On the basis of these considerations, some investigators, including ourselves [51], have 
hypothesised that an impaired parasympathetic innervation of the exocrine glands, and most 
importantly of the salivary and the lachrymal glands, may be one such factor that contributes 
to the loss of secretory function [33,35,52,53]. 
Although studies on an autonomic nervous system dysfunction in pSS were by no 
means numerous in the second half of the 1990s, multiple levels of the cholinergic 
innervation pathway had been studied. The salivary outputs of vasoactive intestinal peptide 
(considered a marker of the parasympathetic innervation) and of neuropeptide Y (a marker of 
sympathetic innervation) were both demonstrated to be increased as compared with those in 
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healthy controls [54]. It was suggested that this phenomenon is associated with an altered 
response to stress in pSS patients. Immunohistological examinations revealed that vasoactive 
intestinal peptide-containing parasympathetic fibres were absent from regions of the parotid 
glands where inflammatory cell infiltration and acinar atrophy were severe [55]. Others 
reported that the expression of the Ph and a isoforms of protein kinase C (PKC), a crucial 
member of the intracellular signal transduction pathway of cholinergic neurotransmission, 
was deficient on the salivary gland acinar epithelial cells in pSS patients as compared with 
controls. In contrast with healthy individuals, the £ and Ph isoforms of PKC were not detected 
on the myoepithelial cells in pSS patients. These findings were suggestive of a postreceptorial 
disturbance of the cholinergic innervation [56]. 
Cardiovascular autonomic neuropathy had been investigated in pSS by various study 
groups [44-50]; however, possibly in consequence of the differences in the methods applied, 
the results were not consistent. Previous studies using various cardiovascular reflex tests 
found signs of a parasympathetic and a sympathetic dysfunction in rather variable proportions 
of the patients (24 to 100% in the various tests) [44-46,49]. Non-invasive [44,49] and invasive 
[46] orthostatic tests revealed only minor differences between pSS patients and controls. A 
more up-to-date way to examine the cardiovascular autonomic nervous system function is the 
computerised measurement of the heart rate variability (HRV), the blood pressure variability 
(BPV) and the spontaneous baroreflex sensitivity (BRS). Short-term HRV examinations 
demonstrated lower a HRV, BPV and BRS in pSS patients than in the controls [50], while 
during 24-hour recordings, the HRV parameters of pSS patients did not differ significantly 
from those of the healthy controls [49]. In contrast, only one article mentioned gastric motility 
in pSS [57], and no clinical trial was published on urogenital involvement. Thus, results 
suggestive of certain disturbances of the cholinergic neurotransmission at both pre-receptorial 
and post-receptorial levels were obtained. 
An important finding of further examinations of this putative autonomic dysfunction 
was that autoantibodies that react with the muscarinic acetylcholine receptor (mAchR) are 
detectable in the sera of pSS patients. Two independent working groups have demonstrated 
that the immunoglobulin-G (IgG) fraction of the sera of pSS patients binds to purified and 
solubilised mAchRs of the mouse and the rat submandibular salivary gland, and behaves as a 
non-competitive agonist of these receptors in a receptor binding assay [58,59]. These 
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observations were based on the following findings: While non-obese diabetic (NOD) mice 
develop a lymphocytic infiltration in the exocrine glands and a sicca syndrome similar to that 
seen in human pSS patients, Igp-null transgenic NOD mice, which are unable to produce 
antibodies do not have an exocrine insufficiency, despite the fact that they develop 
lymphocytic infiltrations in the salivary glands similar to those in the wild-type mice. The 
transfer of pSS IgG to Igp-null transgenic mice led to the loss of saliva production in these 
mice, thereby proving that certain antibodies are responsible for the elicitation of the exocrine 
dysfunction in this murine model of pSS. The above action of pSS IgG was completely 
antagonised with mAchR antagonist agents, demonstrating that an IgG fraction binding to 
mAchR is essential for induction of the sicca symptoms [59,60]. 
Subsequently, the presence of antibodies binding to the human m3AchR, and 
specifically to a synthetic 25mer peptide presumed to correspond to the 2nd extracellular loop 
of the human m3AchR, was also verified in pSS patients [61]. However, in a recent study, the 
authors could not confirm the presence of antibodies reactive with the above synthetic 
peptide. Moreover, it was demonstrated that this sequence, albeit having a 70% homology 
with the human m3AchR section, actually corresponds to the 2nd extracellular loop of the 
human m4AchR [62]. Nevertheless, the authors also failed to detect a reaction between pSS 
sera and the correct peptide fragment of the acetylcholine-binding region of the m3AchR, nor 
with two further epitopes on the m3AchR. Therefore, no conclusive demonstration of the 
presence of antibodies reacting with the human m3AchR, considered a crucial factor in the 
pathogenesis of pSS, has been achieved. 
Inspired by these novel findings, a major part of my research work was an 
investigation of the autonomic nervous system function in pSS patients by means of clinical 
tests, and an attempt to verify the presence of anti-human mAchR autoantibodies in such 
patients. First, in order to investigate the response of the parasympathetic nervous system to 
certain agents directly, we designed an experimental model involving the cutaneous 
microcirculation to test whether there are differences between pSS patients and healthy 
controls in the reaction to the local administration of a muscarinic cholinergic agent. This in 
vivo functional test was also suitable to elucidate whether a putative autonomic disorder exists 
only in the exocrine glands, or is a general phenomenon in pSS. A cholinergic vasodilatory 
mechanism of the human skin blood vessels has long been verified [63-65]. Since this is 
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similar in many respects to the cholinergic innervation of the salivary glands [64], we decided 
to measure the cutaneous vascular response to the local administration of a cholinergic 
agonist, and to use this experimental setting to test the hypothesis that a cholinergic 
dysfunction exists in pSS patients. Second, as the m3AchR is the functionally predominant 
receptor subtype not only in the salivary gland, but also in the gastrointestinal and urogenital 
systems [66,67], we hypothesised that anti-m3AchR antibodies also bind to receptors located 
in these organs and cause an autonomic dysfunction. Therefore, with clinical tests, we 
investigated whether signs of an autonomic dysfunction can be detected in the gastrointestinal 
and urogenital systems. Furthermore, the clinical importance of a cardiovascular autonomic 
neuropathy and the inconsistencies in the results of the previous studies in this field prompted 
us to attempt to clarify the occurrence and severity of a cardiovascular autonomic neuropathy 
by using both the standard cardiovascular reflex tests and the more sensitive and up-to-date 
HRV examinations. Finally, as the presence of autoantibodies to the human m3AchR had not 
been convincingly confirmed, my aim was to develop an experimental system with which to 
examine whether anti-mAchR antibodies can be detected in the sera of pSS patients. 
In conclusion, the aim of these trials was to gain more insight into the mechanisms of 
a putative autonomic nervous system dysfunction in pSS patients. 
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2. Aims 
On this basis, my aims were to investigate the following features: 
1. The presence, occurrence and severity of echocardiographically detectable cardiac 
abnormalities and an oesophageal dysfunction in pSS patients. 
2. The responsiveness of pSS patients to cholinergic stimuli in a microcirculatory 
model. 
3. The frequency and characteristics of an autonomic nervous system dysfunction 
involving the cardiovascular, gastrointestinal and urinary systems in pSS patients. 
4. The development of a diagnostic system for the detection of antibodies reacting 
with human mAchRs and the examination of whether such antibodies are present 
in the sera of pSS patients. 
3. Methods and Results 
3.1. Investigation of cardiac and oesophageal involvement in pSS 
3.1. 1. Cardiac manifestations 
Sixty-four pSS patients (62 female and 2 male, mean age: 59 [SD 12] years, European 
Community criteria [17]) were examined with standard M-mode, two-dimensional and colour 
Doppler echocardiography. Twenty-one age-matched healthy women served as controls. 
The most common abnormal finding in the pSS patients was an impaired left 
ventricular diastolic function, which was revealed in 50% of the 42 patients who could be 
evaluated in this respect. An echogenic pericardium was demonstrated in 21 patients (33%), 
while acute exsudative pericarditis was detected in only one patient. The pulmonary pressure 
was significantly greater in the patients (31 [SD 8] mm Hg) than in the controls (24 [SD 7] 
mm Hg) (p<0.05). 
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3.1.2. Oesophageal involvement 
Twenty-five pSS patients (22 female and 3 male, mean age: 55 [range: 31-75] years, 
European Community criteria [17]) were examined with standard, water-perfusion 
oesophageal manometry. The amplitude, duration and propagation velocity of the contractions 
in the oesophageal body were measured, together with an assessment of the function of the 
lower and upper oesophageal sphincters and the pharyngeal muscles. The results were 
compared with those on 42 healthy controls and were also correlated with the patient 
characteristics and with symptoms related to oral dryness or swallowing disorders. 
In the oesophageal body, we observed an increased duration of peristaltic contractions, 
a decreased propagation velocity and a higher rate of simultaneous contractions for both dry 
and wet swallows. The mean lower sphincter pressure was significantly lower and the mean 
relaxation times were significantly longer in the pSS patients as compared with the controls. 
The predominant motor abnormality appeared to be a decreased oesophageal body peristaltic 
velocity, which correlated with the decrease in both stimulated and unstimulated whole saliva 
production, but with none of the other patient characteristics. 
3.2. Responsiveness of pSS patients to cholinergic stimuli 
3.2.1. Patients and controls 
Twenty-two primary SS patients (20 female and 2 male) were enrolled in the study. 
All were diagnosed as having SS following the European Community criteria [17]. The 
average age of the patients was 50.6 ± 13.2 years (33-60). In order to exclude other factors 
that might possibly influence the microcirculatory physiology, SS patients older than 60 
years, those who had hypertension or clinical evidence of arteriosclerosis (coronary heart 
disease, arteriosclerotic cerebral disease or arteriosclerosis in other organs) or peripheral 
neuropathy, and those who regularly took beta-adrenergic blockers, calcium-channel blockers, 
pentoxyphylline, or other drugs with vasodilatory or anticholinergic properties, were regarded 
as not eligible for the study. For the same reason, the use of non-steroidal anti-inflammatory 
drugs was suspended at least 5 days before the examinations. The patients were asked to 
refrain from smoking or the drinking of coffee on the day of the examination. 
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Twelve healthy, age- and sex-matched individuals were examined as controls. None of 
these subjects had any known illness, or were on any regular medication. 
3.2.2. Examination of the cutaneous vascular response 
During examinations, the patients and the healthy controls were in the supine position. 
The skin blood flow (SBF) was measured with a laser-Doppler flow-meter (Penflux, Perimed) 
attached to the skin on the flexor surface of the right forearm, and blood flow values were 
expressed in arbitrary units [68]. Three ECG electrodes were attached to the chest and the 
heart rate (HR) was monitored continuously, as was the blood pressure (BP) by means of a 
photoplethysmographic BP monitor (Finapres 2300, Ohmeda) attached to a finger of the right 
hand (beat to beat registration). The subjects were asked to lie at rest with their eyes closed. 
The baseline SBF was recorded for 5 minutes; the blood flow was stable by the end of this 
period and the SBF value measured at 5 minutes was defined as SBFbasai- 0.1 ml of carbachol 
(Miostat, Alcon, USA), a muscarinic receptor agonist, was then injected intracutaneously into 
the forearm skin. As control, almost simultaneously, 0.1 ml of 0.9% saline solution was 
injected similarly into the forearm skin at approximately 10 cm from the other injection site. 
SBF was measured simultaneously at the two injection sites for another 10 minutes and the 
highest deviations from the baseline flow values were designated SBFfjnai-
All recorded data (HR, systolic and diastolic arterial BP [SBP and DBP], and SBF) 
were stored in a computer database and were analysed by means of self-developed software. 
The change in SBF in response to the injection of carbachol (dSBF) was calculated via the 
following formula: 
SBFfma|jCarbachol/SBFbasal, carbachol 
dSBF = 
SBFfinal.saline/SBFbasal,saline 
Thus, dSBF is the ratio of the SBF values measured after and before the injection of carbachol 
divided by the corresponding ratio for the control solution of physiological saline. This 
calculation allowed elimination of the absolute flow values and also elimination of possible 
non-specific microcirculatory effects of the intracutaneous injection. In every subject, the 
mean values of the R-R intervals on the ECG, and the systolic, diastolic and mean arterial 
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pressures were also recorded. The cutaneous vascular resistance (CVR) was calculated by 
dividing the mean arterial BP by SBF, while dCVR was calculated with a formula analogous 
to that for dSBF. 
3.2.3. Results 
Table I reports the average values of the most important haemodynamic variables in 
the two groups recorded during the examinations of the cutaneous microcirculation. In the 
event of a positive vascular reaction, the blood flow started to increase within 30 seconds after 
the injection of carbachol and reached a new steady state approximately 4-7 minutes later, 
then remaining unchanged until the end of the examination. In the controls, the average dSBF 
was 3.30 ± 1.79, which was significantly higher than the average dSBF in SS patients (2.07 ± 
1.12) (p=0.019) (Figure I). In the controls, the dSBF values reflected a 1.66-7.6-fold increase 
in microcirculatory blood flow after the injection of carbachol. However, in a relatively high 
proportion of the SS patients, the reaction to the administration of carbachol was small or 
virtually absent, while in other patients a marked vasodilation was observed. We defined a 
positive microvascular reaction to carbachol in the pSS patients as a dSBF value higher than 
Table I. A comparison of certain haemodynamic variables in primary Sjogren's syndrome 
(pSS) patients and controls recorded during the blood flow examinations. 
Group SBFfmal . carba-cho l 
/ 
SBFbasal,carba-chol 
SBFfinai, 
saline 
/ 
S B F b a s a l , 
saline 
d S B F d C V R Mean 
R R I 
(msec) 
Mean 
S B P 
(inmHg) 
Mean 
MBP 
(mmHg) 
Mean 
DBP 
(mmHg) 
pSS 
patients 
1.89 ± 1.05 * 0.94 ± 0.29 2.071 
I . " ! 
0.641 
0.32« 
827.91 
109.6 
132.41 
22.0 
95.91 
16.5 
76.31 
14.9 
Controls 2.72 ± 1.27 0.8610.19 3.301 
1.79 
0.381 
0.17 
797.01 
117.3 
128.61 
14.9 
93.81 
9.8 
74.91 
7.5 
Numbers indicate means ± SD. SBF: skin blood flow; CVR: cutaneous vascular resistance; RRI: RR-interval on 
ECG; SBP: systolic arterial blood pressure; MBP: mean arterial blood pressure; DBP: diastolic arterial blood 
pressure. 
SBF and CVR values are in arbitrary units. For the calculation of dSBF and dCVR, see the text (Section 3.2.2). 
* p = 0.048; f p = 0.019; • p = 0.013 
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the smallest dSBF value in the group of healthy controls. Following this definition, exactly 
half of the SS patients (11 of 22) could be considered to be non-responders, i.e. producing a 
less than 1.66-fold increase in the microcirculatory blood flow, while the other half of the 
patients were regarded as responders to carbachol on the basis of the pronounced 
vasodilatation (a more than 1.66-fold increase in SBF). 
1/b 
8 
• 
7 
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• 
5 • 
Li. 
CO 4 </) 4 •D 
^ 4b ^ 
3 • 
2 • • • • • 
1 
0 
Controls 
Figure 1. The distribution of dSBF values in primary Sjogren's syndrome (pSS) patients and 
healthy controls. 
dSBF: change in skin blood flow in response to the injection of carbachol. The continuous lines indicate means. 
Values above the dashed lines indicate a positive response to carbachol. 
We examined whether there was any difference in certain demographic or clinical 
characteristics between the pSS patients defined as non-responders or as responders to 
carbachol (Table II). No statistically significant difference was observed with respect to any 
of the following parameters: the age of the patients; the time since the appearance of the first 
symptom of pSS; the occurrence of any of the main organ manifestations (but it is noteworthy 
that all the examined organ involvements occurred more frequently in the responder patients 
with the exception of pulmonary fibrosis, which was found in one patient in each of the 
1/a 
8 
7 
6 
5 
dS
B
F 
4 • • 
• 
• 
3 * • 
• • 
2 • 
. > 
• 
1 
0 
pSS patients 
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subgroups); the average values of tear and saliva production; the proportions of patients 
treated with non-steroidal anti-inflammatory drugs, hydroxychloroquine or corticosteroids; 
and the frequencies of anti-SSA, anti-SSB antibody, rheumatoid factor (RF) or antinuclear 
antibody (ANA) positivity. 
Table II. Demographic characteristics and occurrences of certain organ manifestations of 
primary Sjogren's syndrome (pSS) in carbachol-responder and non-responder pSS patients 
Responders 
(n= l l ) 
Non-responders 
(n= l l ) 
Average age (years) 51.0 50.3 
Average time since first symptom (years) 11.8 11.2 
Articular involvement 9 8 
Renal involvement 3 1 
Bronchitis sicca 3 1 
Pulmonary fibrosis 1 1 
Raynaud's phenomenon 5 1 
Skin vasculitis 2 1 
MALT lymphoma in parotid gland 2 0 
For the organ manifestations, the numbers indicate the number of involved patients. Articular 
involvement: arthritis or arthralgia not due to degenerative joint disease. Renal involvement: renal tubular 
acidosis or biopsy-proved tubulointerstitial nephritis. No significant difference was found between the two 
subgroups. MALT: mucosa-associated lymphoid tissue. 
3.3. Clinical trials for the examination of the spectrum of autonomic nervous system 
dysfunction in pSS 
3.3.1. Study patients 
From the cohort of pSS patients followed up at our Department, all who did not have a 
disease that may cause an autonomic neuropathy (e.g. diabetes mellitus or chronic renal 
failure), and were younger than 75 years were enrolled in this study (51 pSS patients [48 
women], average age: 53 [range 31-71] years; American-European classification criteria 
[19]). A questionnaire relating to symptoms which may potentially be caused by an 
autonomic dysfunction was completed by every patient. An answer was considered positive 
when no other medical condition potentially attributable to the elicitation of the symptom was 
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present in the given patient. For the clinical tests, further exclusion criteria were defined; the 
numbers of patients participating in the individual clinical examinations therefore varied. 
3.3.2. Methods - Examination of heart rate and blood pressure variability 
The examination of HRV and BPV is a sensitive method for assessment of autonomic 
neural effects on the cardiovascular system [69]. It is also suitable for measurement of the 
spontaneous BRS. HR and BP were recorded continuously for a period of 10 minutes, with a 
Marquette bedside ECG monitor, and a beat-to-beat plethysmography BP monitor (Finapres 
2300, Ohmeda, St. Louis, MI, U.S.A.), respectively. Signals were recorded on-line and 
digitalised with a Dataq/Windaq system. The data were analysed off-line, using custom 
software (WinCPRS). The following standard HRV and BPV indices were calculated: 
1. Time domain analysis yields descriptive statistical data on the variability of the 
cycle length (R-R wave interval; RRI) and BP values registered during the 10-minute 
examination period: minimum, maximum and mean RRI; SDRR (standard deviation of the 
mean RRI); rMSSD (the square root of the average of the squared differences between each 
consecutive pair of RRIs); pNN50 (the percentage of intervals that differed from the adjacent 
interval by > 50 msec); and the minimum, maximum and mean systolic BP (SBP) (69). 
2. Frequency domain analysis involves power spectral analysis of the effects 
modulating the oscillations in the RRIs and SBP. With a fast Fourier transformation of the 
RRI and SBP values, 2 frequency bands can be produced: low-frequency (LF: 0.05-0.15 Hz) 
and high-frequency (HF: 0.15-0.5 Hz) components. 
3. As the vagus nerve is the efferent pathway of the baroreflex circuit, the 
measurement of BRS provides precise data on the parasympathetic innervation of the heart 
(70). Spontaneous BRS can be assessed at rest during the simultaneous registration of RRI 
and SBP values, as with an intact baroreflex function every spontaneous rise or fall in BP is 
immediately followed by a reduction or elevation of HR. Spontaneous sequences were 
therefore searched for. Spontaneous sequences were defined as three or more consecutive 
cycles of either a SBP elevation (up-sequences) or fall (down-sequences) coupled with RRI 
changes in the same direction. For all of these sequences, the slope of the function of delta 
RRI-and delta-SBP was calculated and averaged separately for up- and down-sequences. 
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As the HRV indices display great variability in the healthy population [71], we 
compared our results on pSS patients with our previous results obtained by the systematic 
examination of a large healthy population [71]. Thus, the results on each pSS patient were 
expressed as percentile values of those for the age- and sex-matched group of healthy 
subjects. Three patients were ineligible for the HRV/BPV examinations because of a previous 
myocardial infarction, a grade III mitral valve insufficiency or frequent extrasystolia (one 
patient each). Since the control group comprised persons with a maximum age of 60 years, 
only pSS patients aged 60 years or below (39 patients, 37 female) could eventually be 
evaluated and compared with a cohort of 559 healthy subjects [71]. The evaluation of BRS is 
feasible only when sufficient numbers of up-BRS and down-BRS sequences are available for 
the statistical analysis. Further patients therefore had to be excluded from the evaluation 
process; finally, up-BRS values could be calculated in 30 patients and down-BRS values in 27 
patients. 
3.3.3. Methods - Cardiovascular reflex tests 
Another approach with which to assess the cardiovascular autonomic nervous function 
is the performance of cardiovascular reflex tests. Five simple, fast and well-reproducible tests 
were carried out following the standard methods of Ewing et al. [72]: 1. HR changes in 
response to deep breathing. 2. HR changes in response to the Valsalva manoeuvre. 3. HR 
changes in response to standing up (30/15 ratio). 4. SBP changes in response to standing up. 
5. DBP changes in response to a sustained handgrip. In every test, normal values were scored 
0, borderline values 1 and abnormal values 2. The sum of the scores gave the total autonomic 
neuropathy score [72]. A score of 0-1 was taken as normal, 2-3 as borderline and >3 as 
abnormal [72]. Of the original 51 patients, 9 were ineligible for the reflex tests because they 
regularly took beta-adrenergic blockers or vasodilating drugs, and the above-mentioned 3 
patients with various organic cardiac abnormalities were also excluded. Thus, the tests were 
performed on 39 patients (37 female) and the results were compared with those on 39 age-
and sex-matched healthy controls. 
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3.3.4. Methods - Examination of gastric emptying 
The gastrointestinal autonomic nervous function was examined by assessment of the 
gastric motility with gastric emptying scintigraphy. Patients with an organic upper 
gastrointestinal disease that may influence the results of the scintigraphic studies were 
regarded as ineligible for this examination. One patient with previous antral surgical 
polypectomy and another patient with pernicious anaemia were therefore excluded. Of the 
remaining subjects, 30 consecutive patients (27 female) participated in this study. The 
examination was performed in the morning after an overnight fast. The patients ingested a 
radiolabeled meal (2 hard-boiled eggs labelled with 20 MBq 99mTc-human serum albumin 
macroaggregate + one bread roll and 200 ml water). A dynamic scintigraphic study was 
performed about the gastric region. Digital images were taken at a frequency of 1 
minute/frame for 2 hours. As a parameter of gastric emptying, the emptying half-time (ti/2), 
i.e. the time until the radioactivity in the stomach had decreased to half the initial value, was 
determined. 
During the validation process of this procedure, the cut-off value for an abnormal Xm 
was determined as the average + 1 SD of the ti/2 values for 7 healthy individuals (6 women) 
with an average age similar to that of the pSS patients. Thus, a ti/2 value >74 minutes was 
considered abnormal. 
3.3.5. Methods - Urodynamic examinations 
For assessment of the autonomic neural effects on the urinary tract, standard 
urodynamic examinations were performed. After detailed diagnostic investigations of the 
pelvic organs, 5 women with cystocele and 3 men with bilateral prostate hypertrophy proved 
to be ineligible for the urodynamic examinations. Six patients refused to participate, and 
finally 16 consecutive patients (all female) underwent the investigation. Uroflow 
measurements and cystometric examinations were carried out in a manner completely 
identical to the routine diagnostic examinations. An overall evaluation of all the clinical data 
and the urodynamic charts was made following the international guidelines for diagnostic 
urodynamic examinations [73]. As an autonomic nervous system dysfunction leads to an 
altered detrusor muscle tone or contractility, the following parameters were considered for the 
purposes of statistical analysis: maximum cystometric bladder capacity (normal: 320-590 ml), 
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peak detrusor pressure (i.e. the difference between the peak intravesical pressure and the intra-
abdominal pressure; normal: 35-60 cmH20), and the maximum urinary flow rate (normal: 15-
36 ml/sec). The normal values we applied are standard values established for adult females 
[73]. 
3.3.6. Results - HRVand BPVexaminations 
The results of the time domain and frequency domain analyses of HRV and BPV in 
the pSS patients are depicted in Figures 2 and 3. For the purpose of comparison with the 
healthy controls, the 37 participating pSS patients were allocated into four subgroups 
according to age and sex: women aged 30-39, 40-49 or 50-59 and men aged 50-59. For each 
of the test parameters, we defined the percentile values in the appropriate age and gender 
subgroup of healthy controls for the results on every patient. The distribution of the percentile 
values for the pSS patients is represented in Figures 2 and 3. It can be seen that the mean RRI 
and SBP values were distributed relatively evenly in the patients, similarly to their 
distribution in the healthy population (p>0.05). In contrast, the SDRR, pNN50, rMSSD, LF-
RRI, HF-RRI and LF-SBP percentile values were clustered in the lowest percentile range, i.e. 
a majority of the pSS patients exhibited parameters that were below the 20th percentile in the 
corresponding age- and sex-matched healthy population. In contrast, the HF-SBP values 
peaked in the high percentile range. The distributions of all the above parameters were 
significantly different from the normal distribution (p<0.001). Figure 4 shows that in almost 
50% of the patients the up-BRS and down-BRS values were below the 20th percentile range, 
while the results on the remainder of the patients were distributed relatively evenly between 
the other percentile ranges (a significant difference from the normal distribution; p<0.05). In 
summary, pSS patients have HR and BP values similar to those in the healthy population, but 
the variability in both HR and BP is restricted and BRS is decreased. 
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Figure 2. Results of time domain analysis of heart rate and blood pressure variability of 39 
primary Sjogren's syndrome (pSS) patients. 
The results are represented as percentile values of those for a group of age- and sex-matched healthy individuals. 
As an illustration, the percentile distribution of the healthy control population is also presented. The distributions 
of the patients in the various percentile ranges are significantly different from the expected distribution for 
SDRR, pNN50 and rMSSD (p<0.001). For the abbreviations and more details, see subsection 3.3.2. 
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Figure 3. Results offrequency domain analysis of heart rate and blood pressure variability of 
39 primary Sjogren's syndrome (pSS) patients. 
The results are represented as percentile values of those for a group of age- and sex-matched healthy individuals. 
As an illustration, the percentile distribution of the healthy control population is also presented The distributions 
of the patients in the various percentile ranges are significantly different from the expected distribution for each 
of the parameters (p<0.001). For the abbreviations and more details, see subsection 3.3.2 
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Figure 4. Results of baroreflex sensitivity (BRS) examinations of 39 primary Sjogren's 
syndrome (pSS) patients. 
The distributions of the up-BRS (30 patients) and the down-BRS (27 patients) values of the patients are 
presented as percentile values of those for a group of age- and sex-matched healthy individuals. As an 
illustration, the percentile distribution of the healthy control population is also shown. The distributions of the 
patients in the various percentile ranges are significantly different from the expected distribution for both the up-
BRS (p<0.001) and the down-BRS (p<0.05) values. For more details, see subsection 3.3.2. 
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Results - Cardiovascular reflex tests 
The proportions of pSS patients who exhibited normal, borderline or abnormal results 
in the individual reflex tests, and their comparison with the results on healthy controls, are to 
be seen in Figure 5. In every test, the higher percentage of pSS patients than that of the 
controls demonstrated an abnormal result (in the statistical analysis, borderline and abnormal 
results were both considered abnormal), and this difference was statistically significant in the 
following tests: the HR responses to deep breathing and standing up, and the DBP change in 
response to a sustained handgrip (p<0.05). When the average values were compared between 
the two groups (Table IV), the pSS patients exhibited significantly lower median values in the 
Table IV. Median values of Ewing's 5 cardiovascular reflex test results in primary Sjogren's 
syndrome (pSS) patients and controls 
Test pSS 
patients 
(median) 
Controls 
(median) 
p value 
Normal Border-
line 
Abnor-
mal 
1. Heart rate change in 
response to deep 
breathing 
>15 11-14 <10 14 21 <0.05 
2. Heart rate change in 
response to the Valsalva 
manoeuvre 
>1.21 1.11-1.20 <1.10 1.48 1.64 >0.05 
3. Heart rate change in 
response to standing up 
(30:15 ratio) 
>1.04 1.01-1.03 <1.00 1 1.12 <0.001 
4. Systolic blood pressure 
fall in response to 
standing up (orthostatic 
test) 
<10 10-29 >30 10 7 >0.05 
5. Diastolic blood pressure 
elevation in response to a 
sustained handgrip 
>16 11-15 <10 16 25 <0.001 
The validated normal values of the tests (72) are also presented. 1. Difference in maximum and minimum heart 
rate (HR) during a period of 6 deep inspirations and expirations (beats/min). 2. Ratio of the longest RR-interval 
registered within 15 seconds after a standardised Valsalva manoeuvre and the shortest RR-interval during the 
manoeuvre (Valsalva ratio). 3. Ratio of HRs measured 15 and 30 seconds after standing up from a supine 
position (beats/min). 4. Drop in systolic blood pressure after standing up from a supine position (mm Hg). 5. 
Difference between the maximum diastolic blood pressure measured within a period of 3 minutes during 
compression of the pressure gauge of a blood pressure meter and baseline diastolic blood pressure value (mm 
Hg). n=39 for both groups, Mann-Whitney U-test. 
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Figure 5. Distributions of results of cardiovascular reflex tests in primary Sjogren's 
syndrome (pSS) patients and controls. 
Figure 5/a: tests mainly relating to parasympathetic function: heart rate changes in response to deep breathing 
(HRV), the Valsalva manoeuvre, and standing up (30/15). Figure 5/b: tests mainly relating to sympathetic 
function: systolic blood pressure changes in response to standing up (orthostatic challenge: ortho) and diastolic 
blood pressure changes in response to a sustained handgrip (handgrip). Total autonomic neuropathy score (AN 
score) results are also presented. Cont: control, NS: non-significant difference. 
tests of the HR response to standing up (p<0.05) and deep breathing (p<0.001), and the DBP 
change in response to a sustained handgrip (p<0.001), while in the two remaining tests, the 
average values of the two groups were not significantly different. Sixteen patients gave 
abnormal and 17 borderline autonomic neuropathy scores (total: 33; 85%), while 1 control 
patient had abnormal and 2 had borderline autonomic neuropathy scores (total: 3; 18%; 
p<0.0001). The median autonomic neuropathy score in the patient group was 3 (range 1-8), 
while that in the control group was 0 (range 0-5; p<0.0001). 
3.3.8. Results - Gastric emptying scintigraphy 
The gastric emptying was significantly slower in the pSS patients than in the healthy 
controls. The average (± SD) ti/2 of gastric emptying was 94 ± 35.9 minutes in the patients and 
59.6 ± 16.7 minutes in the controls (p<0.05). Twenty-one of the 30 pSS patients (70%) 
yielded an abnormal gastric emptying ti/2; moreover, in 9 of them, a markedly elevated \\a 
(more than 120 minutes) was observed. Representative images of the normal gastric emptying 
of a healthy control subject and the prolonged gastric emptying of a pSS patient are shown in 
Figure 6. 
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Figure 6. Radionuclide gastric emptying study of a healthy control subject (Figure 6/a), and 
prolonged gastric emptying of a pSS patient (Figure 6/b). 
Gastric emptying t| /2 was 39 minutes in Figure 6/a, and 171 minutes in Figure 6/b. The graphs show the 
radioactivity (cpm) recorded of the region of the stomach as a function of time (minutes). 
3.3.9. Results - Urodynamic examinations 
We detected an abnormally high bladder capacity in 9 (56%) of the 16 examined pSS 
patients, and an abnormally low capacity in 1 patient (mean: 553 ml, SD: 152 ml). The peak 
detrusor pressure was lower than normal in 6 patients (38%), while a decreased maximum 
uroflow value was found in 5 (31%). At least 1 of the latter 2 tests was abnormal in 9 patients; 
thus, 56% of the patients exhibited some sign of a decreased detrusor muscle contractility. On 
the other hand, for each of the above parameters, one patient demonstrated an abnormally 
high value (different patients in the two tests). Examples of cystometric charts demonstrating 
normal conditions, an abnormally high bladder capacity, and a decreased peak detrusor 
muscle pressure are presented in Figure 7. 
3.3.10. Results - Symptoms and correlations between test results and patient 
characteristics 
The number of patients who experienced particular symptoms potentially 
attributable to an autonomic dysfunction are demonstrated in Table V. 
Table V. Percentages of 51 pSS patients complaining of symptoms possibly attributable to an 
autonomic dysfunction. 
Complaint No.(%) 
Palpitations 9(16) 
Orthostatic hypotension 3(6) 
(Pre)syncope 1(2) 
Postprandial fullness 6(12) 
Vomiting/nausea after eating 1(2) 
Bloating 4(8) 
Diarrhoea 3(6) 
Urge incontinence 4(8) 
Stress incontinence 8(16) 
Difficulty in starting voiding 1(2) 
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Figure 7. Cystometric charts of 3 primary Sjögren 'ssyndrome (pSS) patients. 
Panel A: normal conditions. PaneIB: increased cystometric bladder capacity. Panel C: decreased detrusor 
muscle contractile pressure. The charts represent pressures (cmH20) registered during the examination with 
the intravesical (PI) and the abdominal (P3) manometer, and the detrusor muscle contractile pressure 
calculated as P1-P3. The urinary bladder was filled with sterile isotonic distilled water at an average rate of 
70 ml/min. Sta: start of filling. Fs: time of first sensation of need to void. Pea: peak pressure values during 
voiding. Sto: pressure values at the time point when voiding was intentionally interrupted by the patient. 
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Similarly as in the general population (59), the BRS values displayed a significant negative 
correlation with age (r=-0.44, p=0.012). None of the other test results correlated with age, and 
none of the above test results correlated with the pSS duration, with the presence of any 
extraglandular manifestation or immunoserological positivity, with the stimulated saliva 
production (measured with the Saxon test [74]), or with the results of the sensory nerve 
function test. When the results of the cardiovascular reflex tests were compared between two 
subgroups of pSS patients grouped according to whether or not they had symptoms suggestive 
of a cardiovascular autonomic neuropathy, no differences were found. However, the 9 patients 
who reported palpitations had lower (i.e. more abnormal) values in all of the HRV and BPV 
parameters; this difference was statistically significant in the case of rMSSD (p=0.026) and 
was close to the border of statistical significance in the cases of pNN50 (p= 0.073) and down-
BRS (p=0.076). The presence of the other two symptoms did not correlate with any of the 
results, but the incidence of these symptoms among the patients was very low. 
In all of the patients who had symptoms of an autonomic dysfunction and underwent 
the urodynamic examinations, at least one test result was abnormal. The patient who 
experienced occasional difficulties in starting voiding was found to have both an abnormally 
high bladder capacity and decreased peak detrusor muscle contractions. However, the 
statistical analysis failed to reveal a correlation between the presence of the symptoms and the 
test results on either the urinary or the gastrointestinal system. 
3.4. Preparation of synthetic and recombinant epitopes of human mAchRfor testing of 
their reaction with pSS sera 
3.4.1. Patients 
Sera were collected from 40 pSS patients (38 female, 2 male, mean age: 55 years, 
range: 30-82 years; American-European classification criteria [19]), 24 healthy blood donors 
(mean age: 49 years, range: 23-62 years) and 8 patients with RA (mean age: 56 years, range: 
35-79 years). 
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3.4.2. Recombinant techniques 
Complementary DNA (cDNA), coding for the peptide epitope (K-R-T-V-P-D-N-Q-C-
F-I-Q-F-L-S-N-P-A-V-T-F-G-T-A-I) corresponding to the 2nd extracellular loop of the 
m4AchR, was chemically synthesised as overlapping 5'-phosphorylated oligonucleotides, 
which were hybridised together. The synthetic DNA was digested with restriction enzymes 
and inserted into the expression plasmid pGEX-6P-l, in frame with a sequence coding for 
glutathione-S-transferase (GST) through a BamHl site (monomer form: GST-M4R). In order 
to construct fusions with multiple blocks of the epitope, the cDNA coding for the second 
epitope was produced as above, except that the C-terminal amino acid was followed by a Pro-
Pro-dipeptide in place of the stop codon and by a BglII recognition site. The BamHl and Bgfll 
cut insert was ligated into the BamHl cut plasmid coding for the monomer fusion. As a 
consequence, the two epitope peptides were separated by a Pro-Pro-Arg-Ser tetrapeptide 
(dimer form - GST-M4R-M4R; Figure 8). The inserts and the adjacent regions in all plasmids 
were sequenced by the dideoxy chain termination technique. The recombinant fusion proteins 
were expressed in E.coli, and purified by means of affinity chromatography as described in 
[75], 
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GST-M4R 
GST-M4R-M4R 
GST l—GS — 
I 
AI4R 
GST — G S _ M4R —PPRS — M4R 
Figure 8. Schematic diagrams of the recombinant products containing the antigenic peptide 
epitope of the m4AchR. 
Each recombinant fusion product was composed of GST at the -NH2 end, followed by the antigenic epitope(s) at 
the -COOH terminal. Synthetic DNA sequences were inserted through the BamHl site to the GST gene of the 
fusion expression vector pGEX-6P-l in frame. A dipeptide of GS (one letter code) was inserted between the 
GST and the epitope sequence. In the dimer construct two DNA blocks encoding the peptides were linked to 
one another in frame by the BamHl site without a stop codon. through a sequence coding for a PPRS tetrapeptide 
sequence. Arrows indicate the fusion sites. 
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3.4.3. Enzyme-linked immunosorbent assay (ELISA) techniques 
The amounts of antigens were calculated by equalising the epitope peptide component 
of the monomer and the dimer fusion proteins. Likewise, the amount of GST separately used 
as control for both the monomer and dimer forms was normalised to the GST content of the 
corresponding fusion. Microtiter plates (Costar, high binding capacity) were coated with 0.9 
pg/well GST and 1 pg/well GST-M4R, as well as with 0.4 pg/well GST and 0.5 pg/well GST-
M4R-M4R in 0.1 M Na2C03 buffer, pH 9.6 containing 10 mM dithiotreitol, overnight at 4 °C. 
The plates were then washed twice with phosphate-buffered saline (PBS), pH 7.4, and the 
remaining binding sites were blocked with 2% bovine serum albumin in phosphate-buffered 
saline (PBS) containing 0.1% Tween-20 (blocking solution) for 1 hour at room temperature. 
This was followed by washing with PBS-Tween (PBS containing 0.05% Tween-20). 100 
pl/well of the sera of patients and controls was applied at a dilution of 1/100 in blocking 
solution and incubated for 2 hours at 37 °C. After washing with PBS-Tween, peroxidase-
conjugated antihuman IgG (Sigma) diluted 1:4000 in blocking solution was added to each 
well (100 pl/well), followed by incubation for 1 hour at 37 °C. After washing, the reaction 
was developed with o-phenylene-diamine in phosphate-citric acid buffer, pH 5.0. The colour 
was allowed to develop for 15 minutes at room temperature in the dark. The reaction was 
stopped with 4 N sulfuric acid. The optical density (OD) was measured at 492 nm. Each 
serum was applied in triplicate. The (GST-M4R)-(GST)m nm and (GST-M4R-M4R)-(GST)492 
nm values for the sera of the patients and the controls were determined as measures of the 
peptide-specific reaction. Cut-off values were calculated as x + 2 SD (where x was the mean 
OD for the control subjects). Student's /-test was used to determine whether the differences 
between the groups were statistically significant. 
3.4.4. Results 
As the first step, we chemically synthesised a 25-mer (K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-
S-N-P-A-V-T-F-G-T-A-I) and a 10-mer (K-R-T-V-P-D-N-Q-C-F) amino acid sequence 
corresponding to the 2nd extracellular loop of the m4AchR. Use of a peptide-based ELISA 
system failed to detect a reproducible and well-measurable level of autoantibodies in pSS 
sera, similarly as reported by Cavill et al (62). 
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We therefore studied the application of carrier-bound peptide epitopes instead of the 
peptides alone. Scatter plot diagrams of the reactivities of the sera of pSS and RA patients and 
of healthy controls, determined by ELISA, are shown in Figure 9. With the mean + 2 SD of 
the OD values of the healthy controls taken as the cut-off values, the sera of 2/24 of the 
healthy controls, 12/40 of the pSS patients and 1/8 of the RA patients gave a positive peptide-
specific reaction with the monomer form (Figure 9. a), as did the sera of 0/24 of the healthy 
controls, 28/40 of the pSS patients and 1/8 of the RA patients with the dimer form (Figure 
9.b). The reactions of the sera of the pSS patients with both recombinant fusion peptides 
proved to be highly specific (98% and 100%) and sensitive (58.8 and 76.9%) for the 
monomer and the dimer forms, respectively. 
Table VI presents the mean ODs and the standard deviations of the tested sera in the 3 
groups of subjects. The pSS sera exhibited significantly higher mean ODs than those of the 
healthy controls ( (GST-M4R)-(GST) m nm: 0.196 vs 0.076, p<0.05; (GST-M4R-M4R) -
(GST)492 nm: 0.837 vs 0.285, p<0.0001) (Table Via). Significant differences were observed 
between the pSS and the RA patients as concerns both the monomer (/?=0.0013) and the dimer 
peptide (p=0.0028) (Table Vlb). 
Table VI. Results of ELISA assays with two different coating m4AchR-specific antigens. 
a. 
ELISA antigens 
M4R 
M4R-M4R 
pSS 
0.19610.039 
0.83710.055 
Optical density (492 nm) 
p Healthy control 
0.0246 
<0.0001 
0.07610.011 
0.28510.026 
b. 
ELISA antigens 
M4R 
M4R-M4R 
pSS 
0.19610.039 
0.83710.055 
Optical density (492 nm) 
p RA 
0.0013 
0.0028 
0.14010.058 
0.43610.048 
Values indicate the mean OD 1 SD for all three groups («=40 for pSS, «=8 for RA and «=24 for healthy control 
subjects) for the monomer (a) and dimer (b) forms of the antigen. Microplates were coated with 1 pg/well of 
GST-M4R and 0.5 pg/well of GST-M4R-M4R antigens, respectively, and incubated with the sera at a dilution of 
1:100. 
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Figure 9. Scatter plot of reactivities of sera ofpatients with primary Sjogren's syndrome 
(pSS) or rheumatoid arthritis (RA) and of healthy controls with enzyme-linked immunosorbent 
assay (ELISA). 
A. GST-MR4 as antigen (1 pg/well); B. GST-MR4-MR4 as antigen (0.5 pg/well). Immobilised fusion constructs 
were incubated with patient or control serum (diluted 1:100). Binding of autoantibodies to the immobilised 
antigen was visualised with o-phenylenediamine and H202, after incubation with a peroxidase-labelled 
antihuman IgG (1:4000). The (GST-M4R)-(GST)m nm and the (GST-M4R-M4R)-(GST)m nm optical densities 
(ODs) were considered. The cut-off value was set at the OD of the mean of the negative control sera + 2 SD. The 
cut-off is indicated by the dashed line. 
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4. Discussion 
4.1. Investigation of cardiac and oesophageal involvement in pSS 
Our findings indicate that, while overt cardiac disease is rare in pSS, clinically silent 
changes are common in these patients. Three abnormalities occur in significant proportions of 
the patients: an echogenic pericardium, a left ventricular diastolic dysfunction and an 
increased pulmonary arterial pressure. An echogenic pericardium is most probably a 
consequence of previous symptom-free pericarditis. A precise explanation of the left 
ventricular dysfunction can not be given; vascular or other causes of an impaired myocardial 
relaxation are hypothesised. An increased pulmonary arterial pressure is related to a diffuse 
interstitial lung disease or to direct vascular damage to the pulmonary artery in the involved 
patients. 
In summary, we could identify three types of cardiac abnormalities which seem to 
belong in the clinical spectrum of pSS, as these abnormalities were detected in high 
proportions of pSS patients and no other obvious causes could be identified in the affected 
patients. 
4.1.2. Oesophageal dysfunction in pSS 
A variety of motor abnormalities were revealed in many pSS patients, with a 
decreased oesophageal body peristaltic velocity being the most common (44% of the patients) 
and most significant phenomenon. We concluded that both a diminished saliva production 
and an impaired oesophageal body peristaltic activity are factors in the development of 
swallowing difficulties in pSS. We hypothesised the role of a parasympathetic dysfunction in 
the elicitation of the oesophageal motor abnormalities. 
4.2. Impaired microvascular response to cholinergic stimuli in pSS patients 
In this study, we examined the cutaneous cholinergic vasodilation in pSS patients in 
response to the local administration of a muscarinic cholinergic agonist, carbachol. 
Acetylcholine had been demonstrated to cause vasodilation in healthy humans (64). 
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Carbachol had been demonstrated to induce phospholipase C-dependent saliva secretion 
through stimulation of the muscarinic cholinergic receptors in human salivary acinar cells 
[76,77]. The same muscarinic receptors had been implicated in the cholinergic vasodilation in 
human cutaneous arterioles in response to body heat stress [64]. These findings provided a 
basis for our choice of an investigation of the cutaneous microcirculation as a model of the 
parasympathetic innervation of the salivary glands. 
We found that the average increase in cutaneous microcirculatory blood flow in 
response to carbachol was significantly smaller in the pSS patients than in the healthy 
controls. In half of the pSS patients, the reaction to a potent parasympathomimetic drug was 
virtually absent or markedly diminished. 
This study was among the first involving in vivo examinations of the pathophysiology 
of the autonomic innervatory pathway in pSS patients. Since a muscarinic receptor agonist 
was administered directly to the examined target organ, the detected unresponsiveness was 
strongly suggestive of a dysfunction at a receptorial or postreceptorial level. On the basis of 
these speculations, and supported by contemporary publications [58,59], we hypothesised that 
a likely explanation of a parasympathetic dysfunction in pSS is the interaction of anti-mAchR 
antibodies with the acetylcholine-receptor. More recent investigations seem to lend support to 
our hypothesis [60,78,79]. 
It has been hypothesised that an interaction may occur in the salivary glands between 
the infiltrating inflammatory cells and certain neuropeptides (55). Vice versa, another 
hypothesis suggests that the loss of trophic stimuli from the parasympathetic nerves in the 
salivary glands might be a cause of acinar cell atrophy, and this may contribute to the 
decreased saliva production (55). Our results relating to the investigation of a target organ 
distant from the areas of lymphocytic inflammation suggest that a disorder of the cholinergic 
receptors may not be restricted to the exocrine glands, but may be a more widely occurring 
phenomenon, and that this defect is possibly independent of the local inflammatory process. 
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4.3. Clinical examinations of an autonomic nervous system dysfunction 
The methods applied in this clinical trial were accepted methods for the assessment of 
autonomic neuropathy; however, as anti-AchR autoantibodies are a special feature in pSS, 
and these antibodies may also influence the innervation mechanism, we preferred use of the 
term autonomic dysfunction to autonomic neuropathy. 
As already mentioned in the introduction, the studies of a cardiovascular autonomic 
neuropathy had yielded inconsistent results, in part possibly because of the different methods 
applied. Therefore, we investigated the cardiovascular autonomic dysfunction with both of the 
most widely used methods. The examination of HRV and BPV revealed that, while having a 
normal HR and BP in general, a great majority of the pSS patients have a restricted variability 
of both HR and BP. Our results conclusively indicated that signs of both a sympathetic and a 
parasympathetic cardiovascular autonomic dysfunction can be observed in pSS patients. 
The cardiovascular reflex tests also revealed marked differences as compared with the 
healthy controls, but these data were far less consistent. The ratio of individuals with an 
abnormal result was higher among the patients than among the controls in all 5 tests, but in 
only 2 of the 3 parasympathetic tests and in 1 of the 2 sympathetic tests was this difference 
statistically significant. The autonomic neuropathy score was abnormal in 85% of the pSS 
patients. However, the median global score was 3, which is a borderline value, being much 
lower than that in diabetic patients, in whom average scores of 6 or even higher are the typical 
published values [80,81]. 
It is widely accepted that autonomic reflex tests perform best in diabetic populations 
[72]. Therefore, these tests are well suited for the mass screening and risk stratification of 
diabetics in routine clinical practice [82]. More subtle abnormalities of the cardiovascular 
autonomic regulation might be difficult to assess by reflex test methods. These considerations 
probably explain why we failed to obtain consistent results with the cardiovascular reflex tests 
on pSS patients. Another potential explanation why the previous studies failed to lead to 
conclusive results may be the method of control selection. Age- and sex-matched healthy 
volunteers were recruited, and the control/patient ratio seldom exceeded 1:1. However, some 
of the variables assessed in the present study, such as the spontaneous BRS, had been shown 
to vary tremendously in the healthy population [71,83]. Comparisons with single age- and 
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sex-matched control subjects may therefore be subject to chance influences. Accordingly, we 
related the variables of the pSS subjects to a large database on age- and sex-matched healthy 
volunteers. 
A conclusion of the investigations on the cardiovascular autonomic dysfunction is that 
it is common, but clinically usually relatively mild in pSS. Our patients rarely experienced 
symptoms potentially attributable to it, and significant cardiac symptomatology has not been 
described in studies on large cohorts of pSS patients [11]. Nevertheless, upon direct 
questioning, 9 of the pSS patients (18%) reported episodes of palpitations. Notably, in these 
patients, the autonomic dysfunction was more pronounced than in the pSS patients without 
this symptom when examined with HRV/BPV measurements, while the reflex tests failed to 
identify these patients. We concluded that it is not warranted to routinely test every pSS 
patient, but in occasional pSS patients with complaints suggestive of an autonomic 
dysfunction, short-term HRV/BPV examinations are useful for the verification of an 
underlying autonomic nervous system abnormality, while the cardiovascular reflex tests are 
less valuable in this respect, because of their lower sensitivity. 
In patients with diabetes mellitus, examination of the gastric emptying is an accepted 
method of indication of gastrointestinal autonomic neuropathy [81]. The parasympathetic 
influence predominates in the regulation of the upper gastrointestinal tract motility, including 
the stomach [84]. A loss of vagal tone, resulting in the inhibition of gastric emptying, is 
characteristic of an autonomic neuropathy in diabetes mellitus [85]. By means of gastric 
emptying scintigraphy, severely delayed gastric emptying was observed in many diabetic 
patients [81,86]. Our results indicated that the gastric emptying is prolonged in 70% of pSS 
patients, and a considerable proportion of these patients exhibit a markedly decreased gastric 
motility. As organic changes that may influence the gastric emptying were not detected in the 
patients, this abnormality is most probably a consequence of an impaired parasympathetic 
activity. Data on gastric emptying in pSS patients have been reported in only one study, 
aimed at an evaluation of the oesophageal involvement in scleroderma and pSS (57). 
Similarly to ourselves, the authors found that the gastric emptying was slower in the pSS 
patients than in the controls. It is noteworthy that pSS patients rarely had complaints of an 
impaired gastric emptying, and even the 8 patients in our study who experienced postprandial 
fullness merely had mild symptoms which they reported only upon direct questioning. 
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In our above-mentioned investigations of the oesophageal motor function in pSS 
patients, the predominant abnormality appeared to be a decreased oesophageal body 
peristaltic velocity. As the oesophageal body muscles are partly innervated via the 
parasympathetic nervous system, we suggested a cholinergic autonomic dysfunction as one 
potential explanation of an impaired oesophageal motor function. Those findings are in 
keeping with the results of this study, and suggest that abnormalities in the upper 
gastrointestinal tract attributable to a parasympathetic autonomic dysfunction can be detected 
in a great proportion of pSS patients. However, we note that we failed to reveal a correlation 
between the abnormalities of the gastric and the oesophageal motility measured in 6 patients 
who participated in both trials. 
This was the first report on a systematic search for signs of an autonomic dysfunction 
involving the urinary bladder in pSS patients, despite some reports of urinary retention in 
patients with this disease. However, animal experiments had demonstrated that serum from 
pSS patients has an inhibitory effect on isolated rabbit urinary bladder smooth muscle 
contractions, this effect being mediated by anti-m3AchR antibodies [78]. The normal function 
of the urinary bladder is mainly under the control of the parasympathetic nervous system, 
which facilitates the contraction of the detrusor muscle and . the relaxation of the internal 
sphincter. The loss of parasympathetic stimuli due to sacral plexus injury or diabetic 
autonomic neuropathy leads to urinary retention, bladder atonia or flaccidity [87]. The 
difficulty in starting voiding mentioned by one patient may be explained by a parasympathetic 
dysfunction, for an obstructive disorder had been excluded. Similarly to the results on the 
gastrointestinal system, asymptomatic changes, i.e. an increased bladder capacity, a decreased 
detrusor pressure and a decreased maximal uroflow, were detected in approximately half of 
the patients. As obstructive changes or other organic pelvic diseases were excluded, these 
results are consistent with a decreased detrusor muscle tone and contractility, and, similarly as 
with flaccid neurogenic bladder, a decreased parasympathetic influence can be suspected [87]. 
Finally, we attempted to find an explanation to the finding of the high prevalences of 
the signs of an autonomic dysfunction in all of the examined organs. In view of some marked 
differences from diabetic patients, in whom an autonomic dysfunction is predominantly 
mediated by an autonomic neuropathy, we hypothesised that other factors might also play a 
role in the elicitation of an autonomic failure in pSS patients. A further potential explanation 
38 
of an autonomic dysfunction is the interference of antireceptor antibodies with the normal 
innervation process. Similarly as for the salivary and the lachrymal glands, the functionally 
predominant muscarinic receptor subtype in the gastrointestinal and urinary tracts is the 
m3AchR subtype [66,67], while the heart contains the m2AchR subtype [88]. As the clinical 
pattern of the autonomic dysfunction in the various organs could be explained by the presence 
of anti-mAchR antibodies of different receptor subtype specificities, and some experimental 
data also raised the possibility of antireceptor antibody-visceral organ interactions [78,79], we 
concluded that it is worthwhile to examine whether anti-mAchR antibodies with different 
antigenic specificities may be detected in pSS patients with different clinical patterns of 
autonomic dysfunction. 
4.4. Antimuscarinic-receptor antibody assays 
As already mentioned in the Introduction, the results of the two previous published 
studies involving immunoassays of pSS sera and human mAchR-peptide sequences yielded 
contradictory results. Therefore, we attempted to develop an ELISA assay with a different 
mode of antigen preparation, i.e., with the use of recombinant fusion proteins containing the 
human m4AchR epitope. Nevertheless, in our preliminary experiments, we also produced a 
synthetic m4AchR-specific peptide and its shorter variant, and, similarly to Cavill et al [62], 
we too failed to detect a reliable immunological reaction (data not shown). With regard to 
previous work in the field of peptide-coating techniques, we speculated that the 
physicochemical properties of the peptide used as an immunodominant epitope of the human 
m4AchR (a hydrophobic character and a tendency to form dimers through its two cysteine 
residues [89]) can influence its binding capacity to the microplate and also its antigenicity. 
Subsequently, to avoid the rather problematic peptide-based ELISA system, we 
applied the above-mentioned antigenic peptide with a carrier protein of GST. We did this for 
three reasons: 1. To establish a more standard amount of the coated mass of the antigen, 
which is an important factor in ELISA reactivity. 2. To achieve a better orientation and/or 
conformation of the peptide epitope with the help of the GST moiety. 3. To increase the 
affinity of the antigen for the antibody, since our recombinant strategy permits the 
construction of fusions with dimeric epitope peptides. 
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We have demonstrated that the ELISA investigations with the fusion forms of the 
antigenic peptide are reliable and reproducible. Moreover, use of the dimeric epitope fusion as 
substrate leads to an increase in the sensitivity of the procedure as compared with the use of 
an equal amount of peptide in a single, non-repeated form. With reference to our biochemical 
studies on this topic [90], we consider that the higher efficiency and fidelity of the GST-
homodimer fusion product can be explained by the avidity effect of GST dimer formation and 
a better ligand affinity due to the beneficial conformational consequences provided by the 
protein microenvironment. With optimum adjustment of the procedure parameters, we 
attained a specificity of 100% and a sensitivity of 76.9% for this assay. Although this 
sensitivity is lower than that reported by Bacman et al (61), we believe that the elimination of 
the above-mentioned disadvantages of the peptide ELISA method makes our results 
reproducible. We also expect that a more specific characterisation of the antigenic epitope in 
future studies with the m3AchR will probably lead to assays with improved sensitivity as 
compared with the present one. 
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5. Summary of the results presented in the thesis 
• ad 1: As a co-investigator, I participated in studies which described two previously 
unrecognised features of pSS: an impaired left ventricular diastolic function and an 
echogenic pericardium. After conflicting results in this topic, oesophageal 
manometric studies revealed an impaired oesophageal body peristaltic velocity as 
the major motility disorder in a majority of the patients. 
• ad 2: In one of the first human, functional, in vivo studies, I demonstrated an 
impaired responsiveness of pSS patients to cholinergic stimuli. These results were 
among the first proofs of a parasympathetic dysfunction in pSS. This was the first 
experimental model to prove directly that this unresponsiveness is a general 
feature in pSS (i.e. it is not confined to the exocrine glands), and that it is based 
upon a functional disturbance at a receptorial level. 
• ad 3: With a combination of both previously applied methods, I provided data that 
seem to clarify the occurrence, severity and clinical correlates of a cardiovascular 
autonomic nervous system dysfunction in pSS patients. With the use of human 
clinical tests, I gave the first description of the widespread occurrence of 
disturbances in the urinary parasympathetic innervation, and I was the second to 
demonstrate this phenomenon in the gastrointestinal tract. 
• ad 4: We developed an ELISA system for the detection of recombinant human 
antimuscarinic-receptor antibodies in pSS patients. After previous publications of 
unsuccessful trials in this field, we were able to prove that a majority of pSS 
patients have autoantibodies reacting with human mAchR-specific epitopes, and 
this test identifies pSS patients with considerable sensitivity and specificity. On the 
basis of comparative studies with synthetic and recombinant fusion peptides, we 
explored certain physico-chemical and antigenic characteristics of mAchR 
peptides that may aid in the future development of diagnostic immunoassays for 
anti-mAchR antibodies. 
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7. List of abbreviations 
ANA: antinuclear antibody 
anti-SSA: anti-Sjogren's syndrome A antibody 
anti-SSB: anti-Sjogren's syndrome B antibody 
BP: blood pressure 
BPV: blood pressure variability 
BRS: baroreflex sensitivity 
CD4: cluster of differentiation 4 
cDNA: complementary DNA 
CVR: cutaneous vascular resistance 
DBP: diastolic blood pressure 
dCVR: delta-cutaneous vascular resistance (change in the CVR) 
dSBF: delta-skin blood flow (change in the SBF) 
ECG: electrocardiogram 
ELISA: enzyme-linked immunosorbent assay 
GST: glutathione-S-transferase 
HF-RRI: high-frequency peak of the variability in the R-R wave intervals 
HF-SBP: high-frequency peak of the variability in the systolic blood pressure values 
HLA: human leukocyte antigen 
HR: heart rate 
HRV: heart rate variability 
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IgG: immunoglobulin-G 
LF-RRI: low-frequency peak of the variability in the R-R wave intervals 
LF-SBP: low-frequency peak in the variability in the systolic blood pressure values 
mAchR: muscarinic acetylcholine receptor 
MALT: mucosa-associated lymphoid tissue 
MBP: mean arterial pressure 
MRI: magnetic resonance imaging 
NOD: non-obese diabetic (mouse) 
OD: optical density 
PBS: phosphate-buffered saline 
PKC: protein kinase C 
pNN50: the percentage of R-R wave intervals that differed from the adjacent interval by 
> 50 msec 
pSS: primary Sjogren's syndrome 
RA: rheumatoid arthritis 
RF: rheumatoid factor 
rMSSD: square root of the average of the squared differences between each consecutive 
pair of R-R wave intervals 
RRI: R-R wave interval 
SBF: skin blood flow 
SBP: systolic blood pressure 
SD: standard deviation 
SDRR: standard deviation of the mean R-R wave interval 
SS: Sjogren's syndrome 
X\a'- (emptying) half-time 
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